Volume 5 Supplement 6
Epidemiologic profile of Staphylococcus aureus-methicilin resistant (MRSA) bacterium in hospital-acquired-infection in neonatal-intensive-care-unit (ICU) from -2000 to 2010 analysis in general hospital
© Baqueiro-Freitas et al; licensee BioMed Central Ltd. 2011
Published: 29 June 2011
Introduction / objectives
Awareness of epidemiologic profile of MRSA-hospital-acquired infection in neonatal-ICU might improve an early recognition of this infection.
Evaluating the clinical epidemiologic profile of hospital-acquired Staphylococcus aureus-bacterium infection in neonatal-ICU patients according to its methicilin sensibility.
The infections cases were prospectively recorded for an eleven-year period from 2000 to 2010; the program used was EPI-INFO v 3.4.1.
31 strains of Staphylococcus sp were identified in some hospital-acquired-infections. 46.7% of Staphylococcus aureus were methicilin resistant. Bloodstream infection (BSI) was the most prevalent site of infection of MRSA (40%) as well as for methicilin-sensitive Staphylococcus aureus (MSSA) (62.5%). Symptoms of infection had began as early as 8.5 days and as late as 11 days (average time) from the admission date in methicilin-sensitive and methicilin-resistant Staphylococcus aureus cases respectively. The previous antibiotic therapy was more usual in MRSA cases (80%) than in MSSA (0%). The average weight of newborn infant was heavier in MSSA (2.222g) than MRSA (1626g). The frequency of death was higher in MRSA than MSSA (40% and 12,5% respectivelly). The average duration of stay was slightly longer in MRSA (24 days) than in MSSA (22.8 days).
From that analysis we have pointed out an epidemiologic profile of MRSA-hospital infections in neonatal-ICU concerning its prevalence and others epidemiologic issues in order to prevent its increase and diffusion in neonatal ICU.
Disclosure of interest
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.